[{"id":"37fa384b-e7a2-4ce7-847c-4eaff8ded1d9","acronym":"SPRINT 2","url":"https://clinicaltrials.gov/study/NCT07146230","created_at":"2025-08-30T13:48:56.537Z","updated_at":"2025-08-30T13:48:56.537Z","phase":"Phase 2","brief_title":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","source_id_and_acronym":"NCT07146230 - SPRINT 2","lead_sponsor":"Montefiore Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-08-28"},{"id":"0dede7b9-ee1b-410d-9416-c7e60518928b","acronym":"NSGO","url":"https://clinicaltrials.gov/study/NCT03267589","created_at":"2025-08-02T14:05:36.136Z","updated_at":"2025-08-02T14:05:36.136Z","phase":"Phase 2","brief_title":"Trial in Patients With Relapsed Ovarian Cancer","source_id_and_acronym":"NCT03267589 - NSGO","lead_sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","biomarkers":" CD73","pipe":"","alterations":" ","tags":["CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • tavolixizumab (MEDI0562)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 10/19/2021","primary_completion_date":" 10/19/2021","study_txt":" Completion: 10/19/2021","study_completion_date":" 10/19/2021","last_update_posted":"2025-07-29"},{"id":"57bae4b0-28a5-4fa9-adc4-a7b4d7841588","acronym":"NeoCOAST-2","url":"https://clinicaltrials.gov/study/NCT05061550","created_at":"2021-09-29T11:53:57.404Z","updated_at":"2025-02-25T15:12:20.063Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05061550 - NeoCOAST-2","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • falbikitug (AZD0171) • monalizumab (IPH2201)"],"overall_status":"Recruiting","enrollment":" Enrollment 630","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 05/09/2030","primary_completion_date":" 05/09/2030","study_txt":" Completion: 05/09/2030","study_completion_date":" 05/09/2030","last_update_posted":"2025-02-13"},{"id":"3ec23c8c-cbf9-4200-8659-8f1562c5185d","acronym":"PACIFIC-9","url":"https://clinicaltrials.gov/study/NCT05221840","created_at":"2022-02-05T18:29:09.587Z","updated_at":"2025-02-25T16:38:50.332Z","phase":"Phase 3","brief_title":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05221840 - PACIFIC-9","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Recruiting","enrollment":" Enrollment 999","initiation":"Initiation: 02/07/2022","start_date":" 02/07/2022","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-02-07"},{"id":"2c2514c9-d206-45c0-b6a6-81e2ea36d906","acronym":"Neo-CheckRay","url":"https://clinicaltrials.gov/study/NCT03875573","created_at":"2021-01-18T19:06:29.066Z","updated_at":"2025-02-25T15:08:26.710Z","phase":"Phase 2","brief_title":"Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:","source_id_and_acronym":"NCT03875573 - Neo-CheckRay","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • doxorubicin hydrochloride • cyclophosphamide • oleclumab (MEDI9447)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/06/2019","start_date":" 11/06/2019","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2024-12-20"},{"id":"970c6f47-72fa-4370-9067-ddab6a5a704f","acronym":"SYNERGY","url":"https://clinicaltrials.gov/study/NCT03616886","created_at":"2021-01-18T17:46:20.617Z","updated_at":"2025-02-25T15:07:48.966Z","phase":"Phase 1/2","brief_title":"Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC","source_id_and_acronym":"NCT03616886 - SYNERGY","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • ER • PGR • CD73","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • ER negative","tags":["HER-2 • ER • PGR • CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • paclitaxel • oleclumab (MEDI9447)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 129","initiation":"Initiation: 12/28/2018","start_date":" 12/28/2018","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-19"},{"id":"ef8c69f2-9cbe-4385-a557-591f47dd7101","acronym":"","url":"https://clinicaltrials.gov/study/NCT03381274","created_at":"2021-01-18T16:41:08.185Z","updated_at":"2024-07-02T16:34:37.847Z","phase":"Phase 1/2","brief_title":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","source_id_and_acronym":"NCT03381274","lead_sponsor":"MedImmune LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR T790M negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • oleclumab (MEDI9447) • imaradenant (AZD4635)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 05/08/2018","start_date":" 05/08/2018","primary_txt":" Primary completion: 05/24/2021","primary_completion_date":" 05/24/2021","study_txt":" Completion: 07/15/2025","study_completion_date":" 07/15/2025","last_update_posted":"2024-06-06"},{"id":"84a680b4-a96a-45c2-825f-d8e10004766e","acronym":"BEGONIA","url":"https://clinicaltrials.gov/study/NCT03742102","created_at":"2021-01-18T18:19:46.394Z","updated_at":"2024-07-02T16:35:02.191Z","phase":"Phase 1/2","brief_title":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03742102 - BEGONIA","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • PD-L1 expression + HER-2 overexpression","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • PD-L1 expression + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Truqap (capivasertib) • Datroway (datopotamab deruxtecan-dlnk) • oleclumab (MEDI9447)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 11/14/2024","primary_completion_date":" 11/14/2024","study_txt":" Completion: 11/14/2024","study_completion_date":" 11/14/2024","last_update_posted":"2024-05-21"},{"id":"aa0bda28-21b1-44ee-bd83-6ab69706eeb9","acronym":"ARCHON-1","url":"https://clinicaltrials.gov/study/NCT03801902","created_at":"2021-01-18T18:47:37.181Z","updated_at":"2024-07-02T16:35:02.360Z","phase":"Phase 1","brief_title":"Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial","source_id_and_acronym":"NCT03801902 - ARCHON-1","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/28/2019","start_date":" 10/28/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-05-21"},{"id":"059c44d0-f5a3-4e0a-b39e-6b8103e251ad","acronym":"PIONeeR","url":"https://clinicaltrials.gov/study/NCT03833440","created_at":"2021-01-18T18:55:39.473Z","updated_at":"2024-07-02T16:35:06.100Z","phase":"Phase 2","brief_title":"Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance","source_id_and_acronym":"NCT03833440 - PIONeeR","lead_sponsor":"Assistance Publique Hopitaux De Marseille","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • docetaxel • Orpathys (savolitinib) • ceralasertib (AZD6738) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 10/08/2019","start_date":" 10/08/2019","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-03"},{"id":"ab53141c-faa5-4818-bfa6-8bc2baf852f9","acronym":"DOSa","url":"https://clinicaltrials.gov/study/NCT04668300","created_at":"2024-04-15T18:24:09.850Z","updated_at":"2024-07-02T16:35:09.706Z","phase":"Phase 2","brief_title":"Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma","source_id_and_acronym":"NCT04668300 - DOSa","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • CD8 • PD-1 • CD73 • CD4","pipe":" | ","alterations":" PD-L1 expression • CD73 expression","tags":["PD-L1 • CD8 • PD-1 • CD73 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD73 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/26/2020","start_date":" 11/26/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-15"},{"id":"b10fda2b-447e-4f1a-a80d-b097d7fb22c5","acronym":"MAGELLAN","url":"https://clinicaltrials.gov/study/NCT03819465","created_at":"2021-01-18T18:52:14.035Z","updated_at":"2024-07-02T16:35:17.376Z","phase":"Phase 1","brief_title":"A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC","source_id_and_acronym":"NCT03819465 - MAGELLAN","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 175","initiation":"Initiation: 12/27/2018","start_date":" 12/27/2018","primary_txt":" Primary completion: 05/23/2023","primary_completion_date":" 05/23/2023","study_txt":" Completion: 03/26/2026","study_completion_date":" 03/26/2026","last_update_posted":"2024-02-28"},{"id":"e9745708-7929-4504-9e2d-4c705c19fc86","acronym":"","url":"https://clinicaltrials.gov/study/NCT03611556","created_at":"2023-10-04T01:11:28.511Z","updated_at":"2024-07-02T16:35:34.886Z","phase":"Phase 1b/2","brief_title":"MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.","source_id_and_acronym":"NCT03611556","lead_sponsor":"MedImmune LLC","biomarkers":" NT5E","pipe":" | ","alterations":" CD73 expression","tags":["NT5E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD73 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • oleclumab (MEDI9447)"],"overall_status":"Completed","enrollment":" Enrollment 213","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 07/22/2022","primary_completion_date":" 07/22/2022","study_txt":" Completion: 07/22/2022","study_completion_date":" 07/22/2022","last_update_posted":"2023-10-03"},{"id":"bd4c0ff9-06d4-4a21-b139-a7ee3b5948c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02740985","created_at":"2021-01-18T13:25:31.246Z","updated_at":"2024-07-02T16:35:47.034Z","phase":"Phase 1","brief_title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT02740985","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • docetaxel • Xtandi (enzalutamide) • abiraterone acetate • dexamethasone • oleclumab (MEDI9447) • imaradenant (AZD4635)"],"overall_status":"Completed","enrollment":" Enrollment 313","initiation":"Initiation: 06/17/2016","start_date":" 06/17/2016","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-05-26"}]